Posted by Michael Wonder on 20 Aug 2024
European Commission grants second indication approval for Tepkinly (epcoritamab) for the treatment of adults with relapsed/refractory follicular lymphoma
20 August 2024 - AbbVie today announced that the European Commission has granted conditional marketing authorisation for Tepkinly (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of prior therapy.
Tepkinly is the first and only subcutaneous T-cell engaging bi-specific antibody approved to treat both relapsed/refractory follicular lymphoma and relapsed/refractory diffuse large B-cell lymphoma in the European Union, as well as the European Economic Area countries (Iceland, Liechtenstein, Norway) and Northern Ireland.
